Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PTN with free AI briefings, catalyst countdowns, and dilution alerts.

PTN · PALATIN TECHNOLOGIES INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.5M Cash on Hand
6.3mo Cash Runway
Follow PTN by email Get an email when PTN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PTN, unsubscribe in one click. Privacy

📣 What PTN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
PL9643 Ophthalmic Solution Dry Eye Phase 3 · NCT05201170 Completed
PL-3994 Asthma Phase 2 · NCT01304628 Withdrawn
PL-3994 Aqueous Intravenous Solution Dose… Heart Failure With Preserved Ejection Fraction Phase 2 · NCT04318145 Terminated
PL-3994 Aqueous Intravenous Solution Single Dose Heart Failure With Preserved Ejection Fraction Phase 2 · NCT04318145 Terminated
PL3994 Hypertension Phase 2 · NCT00686803 Completed
PL8177 Ulcerative Colitis Phase 2 · NCT05466890 Active not recruiting
RAAS inhibition therapy Kidney Disease Phase 2 · NCT05709444 Completed

Also used in these trials (approved or third-party drugs, not PTN's own candidates): Bremelanotide, Tirzepatide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PTN holds $7.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.6M/quarter from operations, an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 60 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PTN files for a raise →

👥 Who Owns PTN

Insiders 23.4% Institutions 76.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
Sirenia Capital Management LP Institution (13G, 5%+) 2,307,000 129.54% 2026-03-31
Logos Global Management LP Institution (13G, 5%+) 182,162 10.23% 2026-03-31
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 170,097 9.55% 2025-11-28
DRIEHAUS CAPITAL MANAGEMENT LLC Institution (13G, 5%+) 166,713 9.36% 2025-12-31
Robert K Jr Deveer
Director · +57,780 options
Insider 138,065 7.75% 2025-05-07
Ikarian Capital, LLC Institution (13G, 5%+) 123,132 6.91% 2026-09-30
Carl Spana
President and CEO, Director · +5.15M options
Insider 64,899 3.64% 2026-07-15
Stephen T Wills
Executive VP and CFO/COO · +4.88M options
Insider 63,792 3.58% 2026-07-15
Joseph Stanley Hull
Director · +57,780 options
Insider 42,272 2.37% 2024-07-15
Arlene Morris
Director · +66,604 options
Insider 41,580 2.33% 2024-07-15
Anthony M. Manning
Director · +54,280 options
Insider 36,080 2.03% 2024-07-15
John K A Prendergast
Director · +137,482 options
Insider 15,102 0.85% 2025-12-09

Share count 1,780,939 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PTN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.